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Abstract
Purpose In echocardiography the severity of aortic stenosis (AS) is defined by effective orifice area (EOA), mean pressure 
gradient  (mPGAV) and transvalvular flow velocity  (maxVAV). The hypothesis of the present study was to confirm the patho-
physiological presence of combined left ventricular hypertrophy (LVH), diastolic dysfunction (DD) and pulmonary artery 
hypertension (PAH) in patients with “pure” severe AS.
Methods and Results Patients (n = 306) with asymptomatic (n = 133) and symptomatic (n = 173) “pure” severe AS (mean 
age 78 ± 9.5 years) defined by indexed EOA < 0.6  cm2 were enrolled between 2014 and 2016. AS patients were divided into 
4 subgroups according to  mPGAV and indexed left ventricular stroke volume: low flow (LF) low gradient (LG)-AS (n = 133), 
normal flow (NF) LG-AS (n = 91), LF high gradient (HG)-AS (n = 21) and NFHG-AS (n = 61). Patients with “pure” severe 
AS showed mean  mPGAV of 31.7 ± 9.1 mmHg and mean  maxVAV of 3.8 ± 0.6 m/s. Only 131 of 306 patients (43%) exhibited 
 mPGAV > 40 mmHg and  maxVAV > 4 m/s documenting incongruencies of the AS severity assessment by Doppler echocar-
diography. LVH was documented in 81%, DD in 76% and PAH in 80% of AS patients. 54% of “pure” AS patients exhibited 
all three alterations. Ranges of  mPGAV and  maxVAV were higher in patients with all three alterations compared to patients 
with less than three. 224 (73%) patients presented LG-conditions and 82 (27%) HG-conditions. LVH was predominant in 
NF-AS (p = 0.014) and PAH in LFHG-AS (p = 0.014). Patients’ treatment was retrospectively assessed (surgery: n = 100, 
TAVI: n = 48, optimal medical treatment: n = 156).
Conclusion In patients with “pure” AS according to current guidelines the presence of combined LVH, DD and PAH as 
accepted pathophysiological sequelae of severe AS cannot be confirmed. Probably, the detection of these secondary cardiac 
alterations might improve the diagnostic algorithm to avoid overestimation of AS severity.
Keywords Transthoracic echocardiography · Severe aortic valve stenosis · Left ventricular hypertrophy · Diastolic 
dysfunction · Pulmonary hypertension
Introduction
Aortic valve stenosis (AS) due to degenerative calcifications 
is the most common valvular heart disease [1]. The preva-
lence of severe AS increases with age to 3–4% in individu-
als > 75 years [2]. Recent recommendations for the evalu-
ation of AS by transthoracic echocardiography (TTE) are 
solely performed by Doppler-derived parameters [3]. Peak 
transvalvular flow velocity  (maxVAV), mean transvalvu-
lar pressure gradient  (mPGAV) and effective aortic orifice 
area (EOA) calculated by the continuity equation are rec-
ommended as the primary key parameters to evaluate AS 
severity. Severe AS is characterized by  maxVAV > 4.0 m/s, 
 mPGAV > 40mmHG, EOA < 1cm2 (indexed < 0.6  cm2/m2) 
and/or the ratio between peak velocity determined at the 
level of the LV outflow tract  (maxVLVOT) and  maxVAV < 0.25 
 (maxVLVOT/maxVAV). However,  maxVAV,  mPGAV and EOA 
are frequently incongruent in echocardiographic examina-
tions [4, 5]. With respect to the still un-known incidence 
rate of severe AS the detection of structural and functional 
cardiac alterations might improve the diagnostic criteria 
of severe AS. Pathophysiological consequences due to the 
narrowing of the aortic valve (AV) orifice area, e.g. left 
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ventricular hypertrophy (LVH), diastolic dysfunction (DD) 
and pulmonary artery hypertension (PAH) are generally 
assumed in patients with severe AS. Severe AS induces an 
increase of LV pressure followed by the development of con-
centric LVH. Concentric LVH leads to a higher diastolic 
pressure–volume relationship resulting in an increased LV 
end-diastolic pressure (LVEDP) as evidence of DD. Pul-
monary vascular resistance increases with progression of 
DD indicated by an increase of systolic pulmonary artery 
pressure (sPAP) [6–10]. LVH, DD and PAH are obviously 
cardiovascular alterations due to severe AS, which are pre-
dictive cardiovascular risk factors shown by previous studies 
[11–14]. However, despite the well-known pathophysiology 
of severe AS LVH [15], DD [16] and PAH [17, 18] are not 
observed in all patients with severe AS as reported in the 
literature. Further, LVH, DD and PAH can be induced by 
other diseases independently of AS. According to these cir-
cumstances it might be possible that either the pathophysi-
ological sequelae of AS are not fully understood or that 
patients with hemodynamically not relevant AS will also be 
characterized as severe AS according to current guideline 
criteria [19].
The aims of the present study were to analyze the discrep-
ancies between echocardiographic parameters in patients 
with “pure” severe AS defined by current guideline criteria 
and to analyze the presence of LVH, DD and PAH in these 
highly selected patients with “pure” severe AS [8–10]. It 
was hypothesized that “pure” severe AS is correctly char-
acterized by the accepted pathophysiological sequelae with 
respect to the presence of LVH, DD and PAH irrespectively 
of AS subtypes (classified by  mPGAV and flow conditions).
Methods
In this retrospective study, 745 patients with severe AS 
defined by an EOA < 1cm2 (indexed < 0.6  cm2/m2), who 
underwent transthoracic echocardiography (TTE) at the Uni-
versity Hospital Leipzig between January 2014 and Decem-
ber 2016, were analyzed (Fig. 1). Patients with additionally 
mild to severe aortic regurgitation (AR) and /or concomitant 
moderate or severe mitral and/or tricuspid valve disease were 
excluded. Thus, only AS patients with so-called trace AR 
and mild mitral and/or tricuspid valve disease were enclosed 
(Fig. 1). Because the former definition of trace AR depends 
on color-coded Doppler imaging criteria of the nineties [20, 
21], trace AR was defined by the following criteria: (1) a 
pinhead-sized origin of the regurgitation jet, (2) a pressure 
half time > 750 ms, if continuous-wave (CW) Doppler doc-
umented no intercept angle between the ultrasound beam 
and the direction of blood flow of the regurgitant velocities, 
and/or (3) a non-holodiastolic AR documented by an ana-
tomical colour-M-Mode. Assessment of mitral and tricuspid 
valve disease was performed according to current recom-
mendations [10]. Due to the predefined selection criteria 
the analysis has been performed in a highly selected cohort 
of so-called “pure” AS patients (n = 306; mean age 78 ± 9.5 
years; symptomatic: n = 173; asymptomatic: n = 133), in 
Fig. 1  Flow chart of the selec-
tion criteria defining “pure” AS 
patients. AS = Aortic stenosis; 
EOA = Effective Orifice Area; 
AR = Aortic valve regurgita-
tion; MR = Mitral regurgitation; 
TR = Tricuspid regurgitation
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whom a complete echocardiographic assessment has been 
performed. The entity of “pure” AS is defined as AS without 
concomitant valvular heart diseases. However, these “pure” 
AS patients may have comorbidities, e.g. arterial hyperten-
sion, coronary artery disease, diabetes mellitus etc., which 
obviously do not influence the Doppler echocardiographic 
assessment of AS severity. The study design was approved 
by the local ethical committee. Clinical characteristics of 
the study population were collected from medical records. 
Patients’ treatment has been retrospectively assessed until 
December 2019. Surgical valve replacement (n = 100), tran-
scatheter aortic valve implantation (TAVI, n = 48) or opti-
mal medical treatment (OMT) (n = 156) as well as deaths 
(n = 29) were assessed.
Classification of severe AS
Patients were grouped according to the current recom-
mendations with respect to  mPGAV and indexed LV stroke 
volume (SVi) [10]. Patients with  mPGAV < 40 mmHG 
were defined as low gradient (LG)-AS and patients with 
 mPGAV ≥ 40 mmHg as high gradient-(HG) AS. Patients 
with SVi (assessed by Doppler echocardiography) ≤ 35 ml/
m2 were defined as low flow (LF)-AS and patients with 
SVi > 35 ml/m2 were defined as normal flow (NF)-AS. In 
total, all patients were divided into four subgroups: LFLG-
AS, NFLG-AS, LFHG-AS, NFHG-AS. In addition, patients 
of AS subgroups were defined as AS patients with normal 
(LV ejection fraction (EF) ≥ 55%) and reduced LV systolic 
function (LVEF < 55%) with respect to the proposed grading 
of AS subgroups [22].
Basic echocardiographic examination
TTE was performed using a Vivid e9 or Vivid e95 ultra-
sound system with a M5-S phased array probe (GE Health-
care Vingmed Ultrasound AS, Horten, Norway). Echo-
cardiographic analyses were performed with the EchoPac 
software (Version 202, GE Healthcare Vingmed Ultra-
sound AS, Horten, Norway). The EOA was calculated by 
the continuity equation: EOA = (CSALVOT x  VTILVOT)/
VTIAV (VTI = velocity time integral). The cross-sectional 
area of the left ventricular outflow tract (LVOT)  (CSALVOT) 
was calculated by the following equation:  CSALVOT = π x 
 (DLVOT/2)2. The diameter of the LVOT  (DLVOT) was deter-
mined in the parasternal long axis view (Fig.  2a). The 
Fig. 2  Assessment of effec-
tive Aortic orifice Valve Area 
(AVA) by continuity equation 
(a-c) and determination of 
left ventricular stroke volume 
(LVSV) by Doppler method 
(a,c) and by Simpson’s method 
(d-k). LV = left ventricle, 
LVOT = left ventricular 
outflow tract, 2C = 2-chamber, 
4C = 4-chamber, SV = stroke 
volume, ESV = end-systolic 
volume, EDV = end-diastolic 
volume, EF = ejection fraction, 
Vmax = maximum flow veloc-
ity, maxPG = maximum pres-
sure gradient, meanPG = mean 
pressure gradient VTI = velocity 
time integral, CO = cardiac out-
put, HR = heart rate, CI = car-
diac index, SI = stroke index
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transvalvular VTI  (VTIAV) was assessed by the continuous 
wave (CW)-Doppler and the mean transvalvular velocity 
 (meanVAV) was assessed to calculate  mPGAV applying the 
simplified Bernoulli equation:  mPGAV = 4 x  (meanVAV)2 
(Fig. 2b). The pre-stenotic VTI of the LVOT  (VTILVOT) was 
measured by pulsed wave (PW) Doppler in the apical long 
axis view by positioning the sample volume exactly at  DLVOT 
measurement position (Fig. 2c). The LV stroke volume 
 (SVLV-Doppler) was calculated by the following equation using 
PW Doppler:  SVLV-Doppler = CSALVOT x  VTILVOT. LVEF, LV 
end-diastolic and end-systolic volumes (LVEDV, LVESV) 
and  LVSVLV-bipl  (SVLV-bipl = LVEDV–LVESV) were assessed 
by LV biplane planimetry by the modified Simpson’s rule 
in the apical 2- and 4-chamber view (Fig. 2d–k). Regarding 
both approaches SVi was calculated by dividing LVSV by 
the body surface area (BSA). EOA was also determined by 
replacing  LVSVLV-Doppler with  LVSVLV-bipl [8].
Left ventricular hypertrophy
Relative wall thickness (RWT) was calculated by twice of 
the LV posterior wall diameter (LVPWD) divided by LV 
end-diastolic diameter (LVEDD) (Fig. 3a) [9]. LV mass 
(LVM) was calculated by the following equation: LVM 
(g) = 0.8 × {1.04 × [([LVEDD + diameter of the interven-
tricular septum + LVPWD]3–LVEDD3)]} + 0.6 and indexed 
to the BSA  (LVMi). Normal RWT was defined ≤ 0.42 and 
normal  LVMi was defined ≤ 95 g/m2 (female) or ≤ 115 g/m2 
(male). Using RWT and  LVMi, LV geometry was catego-
rized in four groups: normal LV geometry (RWT ≤ 0.42 and 
normal  LVMi), eccentric LVH (RWT ≤ 0.42 and increased 
 LVMi), concentric LV remodelling (RWT > 0.42 and nor-
mal  LVMi) and concentric LVH (RWT > 0.42 and increased 
 LVMi) [9].
Diastolic dysfunction
Transmitral LV inflow was assessed by PW-Doppler plac-
ing the sample volume at the tips of the mitral leaflets to 
measure E-wave (passive filling), A-wave (atrial contrac-
tion) and E/A ratio (Fig. 3b). E’ was calculated by averaging 
the early passive filling velocity determined by tissue Dop-
pler imaging (TDI) placing the sample volume at the basal 
inferoseptal and lateral mitral annulus (apical 4-chamber 
view) (Fig. 3c) [8]. Indexed left atrial end-diastolic volume 
(LAEDV) was measured by LA planimetry in the apical 2- 
and 4-chamber view at LV end-systole and LAVI > 34 ml/
m2 was defined as abnormal (Fig. 3d,e) [8].
For patients with sinus rhythm (SR), DD grade 2 was 
defined by E/A ≤ 0.8 + E > 50 cm/s or E/A > 0.8—< 2 and 
in presence of 2 out the following 3 parameters (LAVI > 34 
ml/m2, E/E’ > 14 and regurgitation flow of the tricuspid 
Fig. 3  Determination of left ventricular hypertrophy (a), diastolic 
dysfunction (b-f) and pulmonary arterial hypertension (f) by echocar-
diography. IVSd = diameter of interventricular septum, LVIDd = left 
ventricular internal dimension at end-diastole, LVPWd = left ven-
tricular posterior wall diameter, LAEDV = left atrial end diastolic 
volume, TR = tricuspid regurgitation, Vmax = maximum velocity, 
maxPG = maximum pressure gradient, MV = mitral valve
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valve > 2.8 m/s), or DD grade 3 when E/A ≥ 2 [22]. In case 
of atrial fibrillation (AF) DD grade 2 or 3 was defined by 
E/E’ > 11 and/or LAVI > 34 ml/m2 [23]. In all patients with 
SR 3 cycles were averaged, in patients with AF 5 cycles.
Pulmonary artery hypertension (PAH)
sPAP was assessed by measuring maximum velocity of tri-
cuspid regurgitation (TR-Vmax) using CW Doppler (Fig. 3f) 
according to the simplified Bernoulli equation: sPAP = 4 × 
(TR−Vmax)2 adding the estimated central venous pressure 
[8]. sPAP > 35 mmHg was defined as pathological [24].
Statistical analysis
All statistical analyses were performed using SPSS Statis-
tics version 24.0 (IBM, Armonk, NY). Continuous variables 
were expressed as mean value ± standard deviation (SD) and 
were compared between groups using Student’s t-test. All 
categorical variables were expressed as numbers with their 
percentages (%) and compared using chi-squared or Fisher 
exact test, as appropriate. Kolmogorov–Smirnov test was 
performed to test normal distribution of the population. 
Linear regression and Pearson’s r were applied to evaluate 
association between two linear variables. Data comparisons 
between more than two groups were performed by one-way 
Analysis of Variance (ANOVA). A p value < 0.05 was con-
sidered to indicate statistical significance.
Intraobserver variability was assessed by repeating all 
measurements under the same conditions in 20 patients. Fur-
ther, interobserver variability was assessed by measurements 
of a second investigator who was unaware of the results of 
the first examination.
Results
Basic echocardiographic parameters 
and hemodynamics
Only 60 (20%) of 306 (mean age 78 ± 9.5 years; females 
53%) “pure” severe AS patients defined by EOA accord-
ing to current recommendations met all guideline criteria 
for severe AS:  maxVAV > 4 m/s,  mPGAV > 40mmHG and 
 maxVLVOT/maxVAV < 0.25 (Fig. 4). Further, in only 131 
patients (43%) an increased  mPGAV and/or  maxVAV were 
observed (Fig. 4). Thus, 113 patients (37%) were solely 
classified as severe AS by EOA due to continuity equation 
without either a significant increase of  maxVAV or  mPGAV 
or a decrease of  maxVLVOT/maxVAV.
224 (73%) patients showed LG-conditions and only 
82 (27%) showed HG-conditions (Fig. 5). LF-conditions 
were observed in 154 (50%) patients, NF-conditions in 
152 (50%) patients (Fig. 5). Patients with LF-conditions 
were older and had more often AF. Particularly LFLG-AS 
patients showed increased prevalence of comorbidities, 
e.g. arterial hypertension and diabetes mellitus (Table 1).
Normal LVEF was observed in 196 (64%) “pure” 
AS patients, reduced LVEF in 110 (36%) patients. The 
proportion of normal LVEF was significantly higher in 
NFHG-AS patients in comparison to other AS subgroups 
(Table 1 and Fig. 5). LVSV showed significant differ-
ences between  SVLV-Doppler and  SVLV-bipl in patients with 
NF-AS (NFLG-AS: 75.3 ± 11.9 vs. 63.4 ± 18.6 ml/m2; 
NFHG-AS: 84.7 ± 14.5 vs. 66.4 ± 21.1 ml/m2; p < 0.001) 
as well as between indexed  SVLV-Doppler and indexed 
 SVLV-bipl in patients with NF-AS (NFLG-AS: 42.5 ± 6.0 
Fig. 4  Circle diagram to illus-
trate the intersections between 
the presence of  maxVAV > 4.0 
m/s,  mPGAV > 40mmHG, and 
 maxVLVOT/maxVAV in patients 
with “pure” severe AS defined 
by EOA < 0.6  cm2/m2 according 
to current guidelines: EOA < 0.6 
 cm2/m2 was documented in 
113 “pure” AS patients without 
either a significant increase 
of  maxVAV or  mPGAV or a 
decrease of  maxVLVOT/maxVAV. 
 maxVAV = peak transvalvular 
flow velocity;  mPGAV = mean 
transvalvular pressure gradi-
ent;  maxVLVOT/maxVAV = ratio 
between peak velocity deter-
mined at the level of LV outflow 
tract  (maxVLVOT) and  maxVAV
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vs. 35.5 ± 8.5 ml/m2; NFHG-AS: 44.6 ± 6.7 vs. 34.9 ± 10.2 
ml/m2; p < 0.001), whereas no differences were observed 
in LF-AS subgroups (Table 1).
Left ventricular geometry
Most patients showed concentric LVH (n = 243, 79%) irre-
spectively of AS subtypes with an increased presence of 
LVH in NF-AS compared to LF-AS patients (86% vs. 73%; 
p = 0.005). Normal LV geometry was only observed in 7 
LG-AS patients (Table 2).
Diastolic dysfunction
Increased E/E’ (> 14 with SR / > 11 with AF) was observed 
in 212 (69%) “pure” AS patients. LA dilatation was 
observed in 182 (59%) “pure” AS patients with signifi-
cant differences between AS subtypes (Table 3). Increased 
LV filling pressure and at least DD grade 2 were observed 
among 226 (75%) patients, without significant differences 
among AS subtypes (Table 3). Among LV filling velocities, 
A-wave velocities were lower among LF-AS in comparison 
to NF-AS patients (p < 0.001) whereas no differences were 
observed for E-wave velocities. In “pure” severe AS patients 
with SR (n = 194, 60%) 116 patients showed DD grade 2 or 
3. In “pure” severe AS patients with AF (n = 112, 100%) all 
patients showed DD grade 2 or 3 (Fig. 6).
Pulmonary artery hypertension
sPAP was > 35 mmHg in 245 (80%) “pure” severe AS 
patients. It was significantly higher in HG-AS (90%) vs. 
LG-AS (76%) patients (p = 0.007). No differences were 
observed according to flow conditions (p = 0.508) (Table 3).
Prevalence of secondary cardiac alterations
The presence of LVH, DD grade 2 or 3, and PAH as well as 
the incidence of their combination are shown in Table 2 and 
3. One of these secondary alterations were observed in 51 
(17%), two in 90 (29%) and all three in 165 (54%) of “pure” 
AS patients. LG-AS patients had the lowest presence of all 
three secondary alterations–especially LFLG-AS with nor-
mal LVEF and NFLG-AS with reduced LVEF. Patients, in 
whom all three secondary cardiac alterations were present, 
showed higher  maxVAV (3.9 ± 0.9 vs 3.6 ± 0.8, p = 0.002) 
and higher  mPGAV (34.0 ± 16.6 vs 29.3 ± 14.1, p = 0.009).
Symptoms, comorbidities and medication
According to clinical reports 173 (57%) patients with 
“pure” severe AS were classified as symptomatic, although 
also unspecific symptoms e.g. chest pain, vertigo, reduced 
resilience or performance, clinical signs of heart failure 
and/or syncope at rest have been accepted. In 76 (44%) of 
173 symptomatic patients a causal relationship between 
Fig. 5  Selection of the study population with respect to  mPGAV and 
SVi. Patients were divided according to the ESC/EACTS guidelines 
for the management of valvular heart disease (2017). AS = Aortic ste-
nosis; LG = low gradient; HG = high gradient; LFLG = low flow low 
gradient; NFLG = normal flow low gradient; LFHG = low flow high 
gradient; NFHG = normal flow high gradient;  SVi = stroke volume 
index;  mPGAV = mean pressure gradient of the aortic valve; LV = left 
ventricle; EF = ejection fraction
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symptoms and severe AS (angina without coronary artery 
disease and history of hypertension; stress-induced syn-
cope) was highly likely. Unspecific dyspnea was the lead-
ing symptom in all symptomatic patients followed by other 
unspecific symptoms like vertigo and chest pain. The pres-
ence of dyspnea (p = 0.023) and chest pain (p = 0.049) were 
higher in patients with three secondary cardiac alterations in 
comparison to patients with at least one or two. Syncope was 
rare among all AS subgroups. The distribution of symptoms 
did not significantly differ between AS subgroups (Table 1). 
The presence of AF (p < 0.001) and chronic kidney disease 
(p = 0.029) was higher in patients with three secondary car-
diac alterations than in patients with one or two. Between 
AS subgroups, dosages of ß-blockers and statins did not 
Table 1  Baseline characteristics
LFLG low flow low gradient, NFLG normal flow low gradient, LFHG low flow high gradient, NFHG normal flow high gradient, BMI body-
mass-index, CAD coronary artery disease, COPD chronic obstructive lung disease, ACE angiotensin converting enzyme, AR aldosterone recep-
tor, CCB calcium channel blocker, EOA effective orifice area, LV left ventricle, SV stroke volume, ESV end-systolic volume, EDV end-diastolic 
volume, EF ejection fraction, maxVAV peak transvalvular flow velocity of aortic valve, mPGAV mean transvalvular pressure gradient of aortic 
valve
*Significant difference (p < 0.05) with normal-flow low-gradient (NFLG) group. †significant difference with low flow high gradient (LFHG) 
group. ⧧ significant difference with normal flow high gradient (NFHG) group
Variables All Patients (n = 306) LFLG-AS (n = 133) NFLG-AS (n = 91) LFHG-AS (n = 21) NFHG-AS (n = 61) p value
Age, years 78.1 ± 9.0 80.0 ± 8.4*⧧ 77.9 ± 8.9†⧧ 81.1 ± 6.3 ⧧ 73.4 ± 11.6  < 0.001
Female, n 161 (53%) 76 (57%) 49 (54%) 9 (43%) 27 (44%) NS
Atrial fibrillation 112 (37%) 69 (51%)*⧧ 19 (21%)† 14 (67%)⧧ 10 (13%)  < 0.001
Ischemic stroke/TIA 49 (16%) 27 (20%) 12 (12%) 3 (14%) 7 (10%) NS
Hypertension 228 (75%) 105 (79%)* 61 (67%) 16 (76%) 46 (75%) NS
Hyperlipidemia 58 (19%) 25 (19%) 17 (19%) 4 (19%) 12 (20%) NS
Diabetes mellitus 112 (37%) 58 (44%)* 27 (30%) 7 (33%) 20 (33%) NS
CAD 97 (32%) 48 (36%) 27 (30%) 5 (24%) 17 (28%) NS
COPD 29 (9%) 14 (11%) 8 (9%) 2 (10%) 5 (8%) NS
Chronic kidney disease 101 (33%) 49 (37%) 28 (31%) 6 (29%) 18 (30%) NS
Vertigo 62 (20%) 28 (21%) 20 (22%) 5 (24%) 9 (15%) NS
Dyspnea 126 (41%) 56 (42%) 42 (46%) 10 (48%) 18 (30%) NS
Chest pain 44 (14%) 19 (14%) 11 (12%) 4 (19%) 10 (16%) NS
Syncope 10 (3%) 5 (4%) 1 (1%) 1 (5%) 3 (5%) NS
ACE-inhibitor 122 (40%) 48 (36%) 41 (45%) 12 (57%) 21 (34%)  < 0.001
ß-Blocker 170 (56%) 80 (60%)*† 54 (59%)⧧ 10 (48%) 26 (43%) NS
AR-Blocker 77 (25%) 33 (24%)* 17 (19%) 1 (5%) 14 (23%)  < 0.001
Diuretics 159 (52%) 78 (59%)*⧧ 39 (43%)† 16 (76%)⧧ 26 (43%)  < 0.001
Statins 124 (41%) 53 (40%) 37 (41%) 10 (48%) 24 (39%) NS
CCB 67 (22%) 24 (18%)* 29 (32%) 3 (14%) 11 (18%) 0.001
Echocardiographic parameters
EOA,  cm2 0.74 ± 0.15 0.74 ± 0.16*† 0.82 ± 0.15†⧧ 0.52 ± 0.11⧧ 0.72 ± 0.15  < 0.001
maxVAV, m/s 3.8 ± 0.6 3.2 ± 0.6*†⧧ 3.8 ± 0.5†⧧ 4.6 ± 0.4⧧ 4.9 ± 0.6  < 0.001
mPGAV, mmHg 31.7 ± 9.1 21.3 ± 8.9*†⧧ 29.0 ± 6.9†⧧ 49.8 ± 7.6 52.3 ± 13.2  < 0.001
LVSV (doppler), ml 64.2 ± 11.7 48.6 ± 10.3*†⧧ 75.3 ± 11.9†⧧ 55.2 ± 11.1⧧ 84.7 ± 14.5  < 0.001
LVSV (Doppler) index, 
ml/m2
34.8 ± 5.7 26.1 ± 5.1*†⧧ 42.5 ± 6.0†⧧ 28.2 ± 4.6⧧ 44.6 ± 6.7  < 0.001
LVEDV index, ml/m2 55.2 ± 18.6 52.6 ± 21.4⧧ 57.4 ± 16.5 52.6 ± 14.4 58.3 ± 17.1 NS
LVESV index, ml/m2 25.0 ± 13.3 27.7 ± 17.2*⧧ 23.2 ± 10.9 24.1 ± 10.7 22.3 ± 9.5 0.03
LVSV (biplane), ml 57.9 ± 19.4 50.5 ± 19.2*⧧ 63.4 ± 18.6 56.4 ± 19.3⧧ 66.4 ± 21.1  < 0.001
LVSV index (biplane), ml/
m2
31.7 ± 14.2 28.2 ± 20.6*⧧ 35.5 ± 8.5† 28.5 ± 9.0⧧ 34.9 ± 10.2 0.001
Cardiac output (L/min) 4.7 ± 1.1 3.8 ± 1.1*†⧧ 5.1 ± 1.0†⧧ 4.3 ± 1.0⧧ 6.2 ± 1.4  < 0.001
Cardiac index (L/min/m2) 2.5 ± 0.6 2.0 ± 0.6*†⧧ 2.9 ± 0.5†⧧ 2.2 ± 0.4⧧ 3.3 ± 0.7  < 0.001
LVEF, % 55.8 ± 11.0 49.8 ± 13.4*†⧧ 60.5 ± 8.2†⧧ 55.3 ± 11.8⧧ 62.1 ± 9.8  < 0.001
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significantly differ, whereas significant differences were 
observed for ACE-Inhibitors, AR-Blocker, Diuretics, and 
Calcium Channel (Table 1).
Treatment of patients with severe AS
Symptomatic AS patients (n = 173, 57%) were treated by sur-
gery (n = 100, 58%), TAVI (n = 48, 28%) and OMT (n = 23, 
13%), 2 AS patients were lost to follow-up. Symptomatic 
patients were treated by OMT due to different reasons, e.g. 
need for long-term care, severe dementia, patient’s decision, 
refusal of TAVI or surgery, cancer in palliative care (Fig. 7).
All asymptomatic patients (n = 133, 43%) were treated by 
OMT. Until December 2019 12 (7%) symptomatic and 17 
(13%) asymptomatic patients died (Fig. 7).
Inter‑ and intraobserver variabilities
Inter- and intraobserver variabilities of all echocardiographic 
measurements were 9.3% and 7.5%, respectively.
Discussion
The main findings of the present study are:
(1) If “pure” severe AS is assessed by EOA according to 
current echocardiographic recommendations, 54% of 
AS patients presented LVH, DD and PAH in combi-
nation. Thus, the hypothesis of the assumed presence 
Table 2  Parameter of LV geometry
LFLG low flow low gradient, NFLG normal flow low gradient, LFHG low flow high gradient, NFHG normal flow high gradient, RWT relative 
wall thickness, LVMI indexed left ventricular mass
*Significant difference (p < 0.05) with normal flow low gradient (NFLG) group. † significant difference with low flow high gradient (LFHG) 
group. ⧧ significant difference with normal flow high gradient (NFHG) group
Variables All patients (n = 306) LFLG-AS (n = 133) NFLG-AS (n = 91) LFHG-AS (n = 21) NFHG-AS (n = 61) p value
RWT > 0.42 285 (93%) 121 (91%)⧧ 84 (92%)⧧ 19 (90%)⧧ 61 (100%) 0.036
LVMI > 115 g/m2 in 
men and > 95 g/m2 in 
women
256 (84%) 105 (79%)⧧ 78 (86%) 17 (81%) 56 (92%) NS
Normal geometry 7 (2%) 4 (3%) 3 (3%) 0 (0%) 0 (0%) NS
Eccentric hypertrophy 14 (5%) 8 (6%)† 4 (4%) 2 (10%)⧧ 0 (0%) NS
Concentric remodeling 42 (13%) 23 (17%) 10 (11%) 4 (19%) 5 (8%) NS
Concentric hypertrophy 243 (79%) 98 (74%)⧧ 74 (81%) 15 (71%)⧧ 56 (92%) 0.014
Table 3  Parameters of diastolic function in AS subgroups
LFLG low flow low gradient, NFLG normal flow low gradient, LFHG low flow high gradient, NFHG normal flow high gradient, LAVI indexed 
left atrial volume, LAP left atrial pressure, TR tricuspid valve regurgitation
*Significant difference (p < 0.05) with normal flow low gradient (NFLG) group. †Significant difference with low flow high gradient (LFHG) 
group
⧧ significant difference with normal flow high gradient (NFHG) group
Variables All Patients (n = 306) LFLG (n = 133) NFLG (n = 91) LFHG (n = 21) NFHG (n = 61) p value
E-wave velocity, m/s 1.0 ± 0.36 1.05 ± 0.36 0.99 ± 0.35 0.99 ± 0.31 0.98 ± 0.37 NS
A-wave velocity, m/s 0.89 ± 0.39 0.75 ± 0.45*⧧ 1.03 ± 0.35† 0.78 ± 0.34⧧ 1.01 ± 0.33  < 0.001
E/A ratio 1.38 ± 1.18 1.85 ± 1.67*†⧧ 1.06 ± 0.89 0.96 ± 0.46 1.00 ± 0.78  < 0.001
E’, m/s 0.06 ± 0.02 0.06 ± 0.02 0.06 ± 0.02 0.06 ± 0.02 0.06 ± 0.02 NS
E/E’ ratio 19.6 ± 9.6 21.3 ± 11.4*†⧧ 18.8 ± 8.7 17.6 ± 5.1 18.0 ± 8.4 NS
E/ E’ > 14 (11*) 212 (69%) 96 (72%) 62 (68%) 15 (71%) 39 (64%) NS
LAVI, ml/m2 40.8 ± 15.3 41.2 ± 16.7 39.1 ± 12.0 42.3 ± 14.1 41.7 ± 17.7 NS
LAVI > 34 ml/m2 182 (59%) 62 (47%)*† 69 (73%)†⧧ 19 (90%)⧧ 32 (52%)  < 0.001
sPAP, mmHg 47.2 ± 14.9 49.3 ± 18.4* 42.5 ± 10.8†⧧ 51.4 ± 13.2 48.3 ± 13.9 0.002
sPAP > 35 mmHg 245 (80%) 100 (75%)† 71 (78%)† 21 (100%) 53 (87%) 0.014
Increased LAP and Grade 2 
or 3 diastolic dysfunction
228 (75%) 103 (76%) 63 (70%) 18 (81%) 44 (75%) NS
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Fig. 6  Selection of the study population with respect to diastolic dysfunction. SR = Sinus rhythm, AF = Atrial fibrillation; LAVI = indexed left 
atrial volume; TR = Tricuspid regurgitation; LAP = Left atrial pressure
Fig. 7  Retrospective data 
analysis in patients with “pure” 
severe AS until december 
2019. AS = Aortic stenosis; 
TAVI = transcatheter aortic 
valve implantation
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of the accepted pathophysiological consequences of 
severe AS was not confirmed.
(2) LVH, DD and PAH were significantly more often pre-
sent in HG-AS than in LG-AS. Thus, the hypothesis, 
that AS subgroups might have no influence on cardiac 
remodeling, was not confirmed.
(3) According to current guideline criteria (EOA 
indexed < 0.6cm2/m2) an astonishing high proportion 
of LG-AS was observed in “pure” severe AS patients.
(4) Symptoms cannot be used as a convincing criterium to 
characterize AS severity in the elderlies. Most of the 
symptoms are unspecific and a causal relationship can-
not be proven.
(5) Methodologically, no differences were observed for 
LVSV- and SVi-assessment by Doppler echocardiog-
raphy in comparison to LV planimetry in LF-AS. In 
contrast, LVSV- and SVi determined by Doppler echo-
cardiography were significantly higher in NF-AS.
Characterization of the study population
The exceptionality of the present study is that patients with 
concomitant valvular heart diseases which might have 
additional effects on cardiac morphology and function are 
excluded. Thus, pre- and transvalvular Doppler parameters 
are not additionally influenced by concomitant heart valve 
diseases. To our knowledge this is the first comparably pre-
selected study about a cohort of “pure” severe AS patients 
defined by EOA according to current guideline criteria. In 
particular mild AR was excluded because (1) AR might be 
underestimated by semi-quantitative evaluation in patients 
with AS and small cavities, and (2) even mild AR might 
lead to overestimation of flow conditions by determination 
of a higher  SVLV-Doppler. Patients with mitral and tricuspid 
regurgitation were also excluded, because LV and RV vol-
ume overload would have a significant impact on LV and RV 
geometry and pulmonary vascular resistance. In addition, 
AS patients with indexed EOA > 0.6cm2/m2 were excluded 
to avoid non-severe AS due to hyperdynamic state.
The importance of a detailed characterization of the 
echocardiographic inclusion criteria is underlined by the 
differences between  SVLV-Doppler and  SVLV-bipl in NF-AS. In 
the present study  SVLV-Doppler was about 20% higher than 
 SVLV-bipl in NF-AS patients. Obviously, there are methodo-
logical aspects influencing  VTILVOT in NF-AS patients–pre-
sumably because the PW-Doppler sample volume is posi-
tioned in region of the pre-stenotic proximal convergence 
zones or blood flow velocities, which are affected by turbu-
lences due to subvalvular septal bulging–leading to over-
estimation of flow conditions. To our knowledge either 
 SVLV-Doppler or  SVLV-bipl, but not simultaneously both param-
eters have been assessed in previous studies, whereby no sig-
nificant differences have been observed between the different 
flow conditions in severe AS patients [22, 25–32]. However, 
methodological aspects cannot explain the surprising high 
proportion of LG-AS patients in the present study. It can be 
assumed that every amount of AR might have a significant 
influence on  SVLV-Doppler, which will lead to an overestima-
tion of flow conditions. Thus, the relevance of AR in severe 
AS should be analyzed quantitatively in future trials.
In contrast to previous studies AS patients with normal as 
well as reduced LVEF were included, because the continuity 
equation for the assessment of EOA is used regardless of 
an impairment of LV systolic function according to current 
guidelines. It has to be considered that about 39% of LG-AS 
patients had reduced LVEF (presumably due to concomi-
tant coronary artery and hypertensive heart disease) which 
might contribute to the high proportion of LG-AS patients 
in the present study. Especially the number of LFLG-AS 
was fourfold higher than previously reported [22, 33]. This 
might be explained by: (1) the inclusion of symptomatic as 
well as asymptomatic AS patients and (2) the increased age 
of the present population in contrast to the study population 
of Lancellotti et al. reporting only about asymptomatic AS 
in younger patients with normal LVEF [22].
Secondary cardiac alterations in “pure” severe AS – 
concentric LVH, DD, PAH
According to pathophysiological adaptations due to AV 
narrowing, it can generally be assumed that all secondary 
cardiac alterations (LVH, DD and PAH) might be present in 
hemodynamically relevant chronic AS. Thus, the prevalence 
of these alterations is expected to be higher in these patients 
than in the normal age-matched population. However, the 
present data cannot support these pathophysiological seque-
lae, because only 54% of “pure” severe AS patients showed 
all secondary cardiac alterations. In principle, the following 
explanations are possible: (1) it is not fundamentally neces-
sary, that severe AS is accompanied with all secondary car-
diac alterations, (2) it is possible, that the definition of severe 
AS according to current guideline criteria by EOA might 
include also moderate or hemodynamically non-relevant AS 
or (3) a combination of both.
Thus, if non-relevant AS would be classified as severe 
AS by continuity equation, the incidence of combined sec-
ondary cardiac alterations might be supportive to diagnose 
AS severity with a higher probability—especially in “pure” 
severe AS. The proportion of combined LVH, DD and PAH 
was increased in asymptomatic and symptomatic “pure” AS 
patients defined by EOA < 0.6  cm2/m2 with  maxVAV > 4 m/s 
and  mPGAV > 40 mmHg in comparison to LG-AS conceiv-
ably underlining misinterpretation of AS severity – espe-
cially in LG-AS patients.
In previous studies LVH, DD and PAH have also been 
associated with the patients’ outcome [12, 33–37]. Further, 
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LVH implicates a poorer prognosis and higher mortality 
after AV replacement [11]. In the present study, the highest 
E/E’-values were found in LFLG-AS, which may contrib-
ute to the poorer outcome of these patients [22, 25, 38]. 
The presence of DD in AS patients is already known and 
depends on flow conditions [16]. The presence of PAH was 
in line with previous studies [3, 39, 40]. However, signifi-
cantly higher values were observed in LF-AS compared to 
NF-AS (Table 3). An increased pre-operative sPAP showed 
an increased mortality and decreased long term-survival in 
comparison to patients with normal sPAP prior to surgery 
[39, 40].
Correlation of symptoms to AS severity
Cardinal symptoms of severe AS are stress-induced angina, 
dyspnea and/or syncope [9, 10]. However, the precise preva-
lence of symptoms in patients with severe AS is still not 
known, because the causal relationship between symptoms 
and AS severity is hard to define. However, most of the 
symptoms are unspecific and cannot conclusively be asso-
ciated with AS in the elderlies. Thus, it is not surprising 
that the occurrence of symptoms is usually not suitable for 
characterization of AS severity.
In the present study LF-AS patients tend to be older in 
comparison to NF-AS. Further, AF tend to be observed more 
often in LF-AS. The correlation between AF and increased 
LA pressure as well as age is already known and in agree-
ment with previous studies [41, 42].
Further Classification of AS
Generaux et al. presented an echocardiographic classifica-
tion regarding the outcome of patients with severe AS based 
on an extent of structural cardiac changes (abnormalities of 
LV, RV, LA and mitral or tricuspid valve). Concomitant val-
vular heart diseases obviously have had a significant impact 
on the patients’ outcome [43, 44]. The patients` cohort of the 
present study cannot be compared to these data, because all 
further relevant valvular heart diseases have been excluded.
Limitations
The selection of “pure” severe AS patients defined by EOA 
assessment explains the relatively small number of AS 
patients in the present study. However, these highly selected 
severe AS patients without concomitant valvular heart dis-
eases highlight the exceptionality of the present cohort. 
This retrospective cross-sectional study does obviously not 
allow conclusions about the patients’ outcome and the devel-
opment of LVH, DD and PAH with disease progression. 
The follow-up until 12/2019 documented a high percent-
age of AV treatment in symptomatic severe AS patients. In 
addition, the prevalence and the incidence rate of secondary 
cardiac alterations in AS patients with concomitant valvular 
heart diseases have to be analyzed in further trials. In the 
present study assessment of LV remodeling and AS severity 
by cardiac magnetic resonance (CMR) could not be per-
formed due to missing CMR data sets. Probably, the small 
sample size of LFHG-AS has an impact of the statistical 
significance between AS subgroups.
Conclusions
The echocardiographic characterization of “pure” severe AS 
based on EOA by the continuity equation might implicate 
diagnostic incongruencies. In patients with “pure” severe 
AS according to current guideline criteria the presence of 
combined LVH, DD and PAH as accepted pathophysiologi-
cal sequelae cannot be confirmed. Probably, the detection 
of these secondary cardiac alterations might improve the 
diagnostic algorithm to avoid overestimation of AS sever-
ity. The high proportion of LG-AS in this preselected cohort 
highlights the importance of concomitant valvular diseases 
for characterizing flow conditions in AS patients. In addi-
tion, flow conditions might be overestimated by  SVLV-Doppler 
assessment in presence of (even mild) AR. Thus, these find-
ings might have implications on future echocardiographic 
AS classification. The present study sets the stage for follow-
up studies to determine the prognostic value of secondary 
cardiac alterations in “pure” severe AS.
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